WS #10414

From 499 msgs · 8 key-dev

AbbVie acquires Apogee Therapeutics for $10.9B all-cash ($135.11/share), a ~60% premium, adding zumilokibart to pipeline.

Biotech M&A: AbbVie-Apogee

AbbVie acquires Apogee Therapeutics for $10.9B all-cash ($135.11/share), a ~60% premium, adding zumilokibart to pipeline.

Full world state #10414 →